Label Changes for:
Xopenex (levalbuterol HCl) Inhalation Solution Concentrate, 1.25 mg/0.5 mL
Changes have been made to the ADVERSE REACTIONS sections of the safety label.
Detailed View: Safety Labeling Changes Approved By FDA Center for Drug Evaluation and Research (CDER) – September 2012
Postmarketing Adverse Reactions
- metabolic acidosis.....added